You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: PATHMAKER MOBILITY CORP. Topic: 109
PROJECT SUMMARY / ABSTRACT Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motor neurons in the spinal cord and brain. ALS causes muscle weakness and paralysis and eventually death. According to the ALS Association, every 90 minutes there is a new diagnosis of ALS, as well as an associated death. Nearly 5,000 people are diagnosed with ALS each year and a ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Chesapeake Genomic Systems LLC Topic: 400
In vitro assembly of DNA fragments andgt;20 kb has recently identified as a critical technical challenge for writing synthetic genomes. Meeting this challenge will increase the efficiency of genome writing projects that depend on large synthetic DNAs, which are iteratively recombined to replace chromosome regions in a step-wise manner to partially or completely re-write bacterial or yeast chromoso ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent DeliverySBC: MERCATOR MEDSYSTEMS, INC. Topic: NHLBI
PROJECT SUMMARY Post-thrombotic syndrome (PTS) is a chronic debilitating condition characterized by limb swelling and discomfort, hyperpigmentation, skin ulcers, and impaired quality of life. It occurs within 2 years of deep vein thrombosis (DVT) treatment in 50-60% of patients with iliofemoral thrombosis and in 30-50% of all DVT patients regardless of thrombosis location (1). Even with pharmacolo ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: OSSIUM HEALTH INC Topic: NHLBI
PROJECT SUMMARY Mesenchymal stem cells (MSC) are in clinical development for cardiovascular, neurologic, orthopedic, and other indications. Ossium is developing a novel source of MSC from vertebral bodies (vbMSC). Genetic modification of vbMSC using lentiviral vector (LV) has the potential to improve the therapeutic potential. Understanding how genetic modification might alter the vbMSC phenotype ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: General Biophysics LLC Topic: NIA
Administrative Supplement Application PA-20-272 Xenon gas treatment to modulate microglia in neurodegenerative diseases (R41AG073059) ABSTRACT ABSTRACT FROM ORIGINAL APPLICATION Alzheimer’s disease (AD) is the most prevalent neurodegenerative disorder. Emerging evidence shows that homeostatic dysregulation of the brain immune system, especially that orchestrated by microglia, plays a significant ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Biopac Systems, Inc. Topic: NIBIB
Abstract Magnetic resonance imaging (MRI) is critically important for pediatric care and the unusable data caused by patient motion has been estimated to cost $1.4B per year in the United States alone. Currently, a radiologist assesses if the images are satisfactory or not, but an MRI technologist does the imaging, and coordination of communication between the two is costly and slow. We propose to ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: Hillhurst Biopharmaceuticals, Inc. Topic: 107
PROJECT SUMMARY The goal of the proposed project is to evaluate the potential of HBI-002, a novel oral formulation of carbon monoxide (CO), as a neuroprotective agent in Parkinson’s disease (PD). A growing body of research suggests that low doses of CO - and the heme oxygenase (HO) enzymes that generate endogenous CO - protect against neuronal cell loss in PD, and epidemiologic studies have asso ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
A Novel Therapeutic that Harnesses Microtubules to Promote Cavernous Nerve Regeneration after Radical ProstatectomySBC: MICROCURES INC Topic: 300
Radical prostatectomy (RP) is a commonly used treatment option for localized prostate cancer, which carries a high risk for development of erectile dysfunction (ED) because of cavernous nerve (CN) injury. Even newer, nerve-sparing, robotic procedures do not convincingly improve erectile function (EF) outcomes after RP. In addition, ED resulting from RP is often refractory to treatment by orally ad ...STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
SBC: POINT DESIGNS, LLC Topic: NIBIB
Multi-Modal Fingertip Sensors for Prosthetic HandControl and FeedbackPROJECT SUMMARY / ABSTRACT The goal of the proposed project is to develop a robust, multi-modal prosthetic fingertip sensor – the Point Touch – which 1) has a patented multi-modal sensing capability including measurement of proximity, contact, and force and 2) can augment myoelectric control methods using semi-autonomous cont ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
EXODUS-enabled High-throughput Multi-omics Profiling of Extracellular Vesicles for Diagnosis of Preclinical Alzheimer's DiseaseSBC: WELLSIM BIOMEDICAL TECHNOLOGIES INC Topic: NIA
PROJECT SUMMARY / ABSTRACT Alzheimerandapos;s disease (AD) is the most widespread neurodegenerative disorder and has caused a major global health concern with the aging population. Early diagnosis of AD before irreversible brain damage or mental decline is critical for timely intervention, symptomatic treatment, and improved patient function. Accumulating studies indicate that neuron-derived extra ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health